Jiangsu Chia-Tai Tianqing Pharmaceutical and Advenchen Laboratories are 
co-developing anlotinib (Focus V®) for the treatment of advanced cancer. 
Anlotinib is an oral small molecule inhibitor of multiple receptor tyrosine 
kinases, with a broad spectrum of inhibitory effects on tumour angiogenesis and 
growth. Anlotinib is approved in China for the treatment of patients with 
locally advanced or metastatic non-small cell lung cancer (NSCLC) who have 
undergone progression or recurrence after ≥ 2 lines of systemic chemotherapy. 
Anlotinib is also undergoing phase II and/or III clinical development for 
various sarcomas and carcinomas in China, USA and Italy. This article summarizes 
the milestones in the development of anlotinib leading to this first approval 
for NSCLC.